Stock Markets July 9, 2026 05:34 PM

Solaris Energy Gains After S&P SmallCap 600 Inclusion Announced

Shares tick higher as firm is set to replace Catalyst Pharmaceuticals in the S&P SmallCap 600 ahead of July 15 trading

By Derek Hwang
Share
Twitter Reddit Facebook LinkedIn
SEI CPRX

Solaris Energy Infrastructure Inc saw its stock advance in after-hours trading after S&P Dow Jones Indices confirmed the company's imminent addition to the S&P SmallCap 600 index. The change, effective before the market opens on Wednesday, July 15, will remove Catalyst Pharmaceuticals from the benchmark as Catalyst is acquired by Angelini Pharma S.p.A. The move may draw purchases from index-tracking funds and affects Solaris' visibility among passive investors.

Solaris Energy Gains After S&P SmallCap 600 Inclusion Announced
SEI CPRX
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Index inclusion often leads to purchases by passive funds, potentially increasing demand for Solaris shares - impacting equity markets and passive fund flows.
  • Solaris operates in power generation equipment and logistics for oil and gas well completion, linking it to the energy and oilfield services sectors.
  • Catalyst Pharmaceuticals is being removed from the SmallCap 600 because it is being acquired by Angelini Pharma S.p.A., a transaction expected to close soon pending final conditions.

Solaris Energy Infrastructure Inc (NYSE:SEI) experienced a 3.6% gain in after-hours trading on Thursday following an announcement from S&P Dow Jones Indices that the company will be added to the S&P SmallCap 600 index.

The index change will take effect prior to the opening on Wednesday, July 15. Solaris will be added in place of Catalyst Pharmaceuticals Inc. (NASDAQ:CPRX), which is being acquired by Angelini Pharma S.p.A. in a transaction that is expected to close soon, subject to final closing conditions.

Solaris Energy Infrastructure supplies modular, scalable equipment-based solutions that support power generation, control and distribution, and the handling of raw materials used in completing oil and natural gas wells across the United States. The company reports results through two operating segments: Solaris Power Solutions and Solaris Logistics Solutions.

Inclusion in a widely followed index such as the S&P SmallCap 600 often leads to increased buying from passive investment vehicles that track the benchmark. Those funds typically must purchase shares of stocks newly added to the index to keep their holdings aligned with the index composition, which can raise demand for the added companys shares.

The announced replacement of Catalyst Pharmaceuticals follows that company's pending acquisition by Angelini Pharma S.p.A., a transaction noted by S&P Dow Jones Indices as the reason for the vacancy in the SmallCap 600 that Solaris will fill. The timing of the index adjustment is set so that Solaris will begin trading as a component before markets open on July 15.


Summary

  • Solaris Energy Infrastructure shares rose 3.6% in after-hours trading after S&P Dow Jones Indices disclosed the company's addition to the S&P SmallCap 600.
  • The change is effective prior to the opening on Wednesday, July 15, with Solaris replacing Catalyst Pharmaceuticals, which is being acquired by Angelini Pharma S.p.A.
  • Solaris operates two segments - Solaris Power Solutions and Solaris Logistics Solutions - and provides modular equipment solutions for power generation and oil and natural gas well completion.

Key points

  • Index inclusion typically draws purchases from passive funds tracking the SmallCap 600, which may increase demand for Solaris shares - impacting equity markets and passive fund flows.
  • Solaris' business spans power generation equipment and logistics for oil and natural gas well completion, tying the company to the energy and oilfield services sectors.
  • The replacement of Catalyst Pharmaceuticals is driven by Catalyst's pending acquisition by Angelini Pharma S.p.A., creating the opening Solaris will occupy in the index.

Risks and uncertainties

  • The acquisition of Catalyst Pharmaceuticals remains subject to final closing conditions; any delay or failure could affect index composition plans and associated market moves - relevant to index funds and small-cap equity investors.
  • Index-driven demand is not guaranteed; while passive funds often buy newly added components, actual flows and price effects depend on fund strategies and market conditions - affecting liquidity and short-term price behavior in Solaris stock.

Risks

  • The Catalyst Pharmaceuticals acquisition remains subject to final closing conditions; any change could alter index composition plans and related market responses - relevant to index funds and small-cap equity investors.
  • Index-driven buying by passive funds is typical but not guaranteed; actual fund flows and resulting price effects depend on fund behavior and prevailing market conditions - affecting liquidity and short-term share performance.

More from Stock Markets

CCC Intelligent Solutions Engages Morgan Stanley to Explore Strategic Options, Including Possible Sale Jul 9, 2026 AWS launches Loom for AWS to standardize secure AI agent lifecycles Jul 9, 2026 B. Riley Names VSE Corporation Its Top Aerospace & Defense Pick, Sees Margin Upside Jul 9, 2026 Mexican equities slide as S&P/BMV IPC loses 0.75% amid sector weakness Jul 9, 2026 Colombian equities close lower as COLCAP dips 0.87% amid sector losses Jul 9, 2026